Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciaf130 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Patrícia Ramgi und 39 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Nacional de Saúde, Maputo, Mozambique. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Immunogenicity, Vaccine, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coalition for Epidemic Preparedness Innovations.
Abstract (Originalsprache)
Background
Data on immunogenicity and safety of heterologous prime-boost (HePB) regimens using the BBIBP-CorV and Ad26.COV2.S have not yet been reported in sub-Saharan Africa.
Methods
We conducted a randomized, observer-blinded, non-inferiority trial assessing the immunogenicity and safety of HePB regimens using BBIBP-CorV and Ad26.COV2.S, in adults aged 18–65 years. Participants enrolled, were stratified by baseline severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serostatus, and randomized into four arms in a 1:1:1:1 ratio: A1 (BBIBP-CorV, Ad26.COV2.S), A2 (BBIBP-CorV, BBIBP-CorV), B1 (Ad26.COV2.S, BBIBP-CorV), and B2 (placebo, Ad26.COV2.S), administered at 28-day intervals. Fifteen participants in each arm were randomized separately in the immunology subset at a ratio of 1:1:1:1. Primary endpoints were the geometric mean titers (GMTs) of anti–SARS-CoV-2 neutralizing antibodies (nAbs) against SARS-CoV-2 Omicron variant BA.1 and safety at 4 weeks after second vaccination. The non-inferiority margin was 0.67 fold difference in geometric mean ratio (GMR) between the ratio of GMTs in the heterologous versus corresponding homologous arms.
Results
A total of 369 participants were randomized, and 367 of them received at least one dose of vaccine. Participants were between 18 and 65 years of age. Four weeks after second dose, GMT of nAbs in arms A1 and A2 was 802.7 (95% confidence interval [CI]: 635.3–1014.3) and 202.6 (95% CI: 150.8–272.1), respectively, with an adjusted GMR of 4.2 (2-sided 95% CI: 2.9–5.9). GMTs were 603.6 (95% CI: 446.1–816.7) and 725.7 (95% CI: 539.5–976.1) in arms B1 and B2, respectively, with an adjusted GMR of 0.8 (2-sided 95% CI: .5–1.2). Three serious adverse events were reported and none of them were related to the vaccination.
Conclusions
The noninferiority criterion was met only in arm A1 versus A2. HePB regimens were safe and well tolerated. Clinical Trials Registration NCT04998240.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto Nacional de Saúde, Maputo, Mozambique.
- International Vaccine Institute, Seoul, Republic of Korea.
- Burkina Institute of Global Health, Ouagadougou, Burkina Faso.
- Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar.
- Department of Medicine, Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, United Kingdom.
- China National Biotec Group Company Limited, China.
ORCID-Profile: Patrícia Ramgi, Odete Bule, Eun Lyeong Park, Carina Fernando, Herinirina L Derandrainy, Carmélia Massinga, Hyon Jin Jeon, Jean-Louis Excler, Jonathan D Sugimoto, Tabea Binger, Asma B Aziz, Ilesh V Jani, Birkneh Tilahun Tadesse, Florian Marks
Förderung
- Coalition for Epidemic Preparedness Innovations
Zitieren
APA
Ramgi, P., Siribie, M., Rakotozandrindrainy, N., Bule, O., Shrivastava, H., Chambule, L., Park, E. L., Fernando, C., Boque, J., Macuiana, R., Razafimanantsoa, R., Rakotozandrindrainy, N., Razafindrabe, T. J. L., Rakotoarisoa, A. N., Raminosoa, T. M., Derandrainy, H. L., Rakotoson, M. M., de Silva, C. S. S., Mutombene, M., …, & Marks, F. (2025). Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf130
Vancouver
Ramgi P, Siribie M, Rakotozandrindrainy N, Bule O, Shrivastava H, Chambule L, et al. Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf130
BibTeX
@article{Ramgi2025,
author = {Ramgi, Patrícia and Siribie, Mohamadou and Rakotozandrindrainy, Njariharinjakamampionona and Bule, Odete and Shrivastava, Harshvardhan and Chambule, Lígia and Park, Eun Lyeong and Fernando, Carina and Boque, Jéssica and Macuiana, Rezelda and Razafimanantsoa, Ravomialisoa and Rakotozandrindrainy, Ndrainaharimira and Razafindrabe, Tsiriniaina J L and Rakotoarisoa, Antenaina N and Raminosoa, Tiana M and Derandrainy, Herinirina L and Rakotoson, Masinirina M and de Silva, Cynthia S S and Mutombene, Mirna and Massinga, Carmélia and Langa, José P and Guarnacci, Tobin and Kang, Sophie S Y and Jo, Sue Kyoung and Jeon, Hyon Jin and Excler, Jean-Louis and Yang, Yunkai and Wang, Shiyu and Sugimoto, Jonathan D and Yang, Jae Seung and Shim, Byoung-Shik and Binger, Tabea and Capitine, Igor U and Aziz, Asma B and Park, Ju Yeon and Kim, Deok Ryun and Rakotozandrindrainy, Raphaël and Jani, Ilesh V and Tadesse, Birkneh Tilahun and Marks, Florian},
title = {Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciaf130}
}
EUVIMED